Thomas Cash1, Elizabeth McIlvaine2, Mark D Krailo2, Stephen L Lessnick3, Elizabeth R Lawlor4, Nadia Laack5, Joel Sorger6, Neyssa Marina7, Holcombe E Grier8, Linda Granowetter9, Richard B Womer10, Steven G DuBois11. 1. Department of Pediatrics, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia. 2. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. 3. Center for Childhood Cancer and Blood Disorders at Nationwide Children's Hospital, and the Division of Hematology, Oncology and BMT at The Ohio State University, Columbus, Ohio. 4. Department of Pediatrics, University of Michigan, Ann Arbor, Michigan. 5. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. 6. Department of Orthopedics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 7. Department of Pediatrics, Stanford University School of Medicine and Lucille Packard Children's Hospital at Stanford, Palo Alto, California. 8. Department of Pediatrics, Children's Hospital Boston/Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 9. Department of Pediatrics, NYU School of Medicine and NYU Langone Medical Center, New York. 10. Department of Pediatrics, University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 11. Department of Pediatrics, UCSF School of Medicine and UCSF Benioff Children's Hospital, San Francisco, California.
Abstract
BACKGROUND: The prognostic significance of having extraskeletal (EES) versus skeletal Ewing sarcoma (ES) in the setting of modern chemotherapy protocols is unknown. The purpose of this study was to compare the clinical characteristics, biologic features, and outcomes for patients with EES and skeletal ES. METHODS: Patients had localized ES and were treated on two consecutive protocols using five-drug chemotherapy (INT-0154 and AEWS0031). Patients were analyzed based on having an extraskeletal (n = 213) or skeletal (n = 826) site of tumor origin. Event-free survival (EFS) was estimated using the Kaplan-Meier method, compared using the log-rank test, and modeled using Cox multivariate regression. RESULTS: Patients with extraskeletal ES (EES) were more likely to have axial tumors (72% vs. 55%; P < 0.001), less likely to have tumors >8 cm (9% vs. 17%; P < 0.01), and less likely to be white (81% vs. 87%; P < 0.001) compared to patients with skeletal ES. There was no difference in key genomic features (type of EWSR1 translocation, TP53 mutation, CDKN2A mutation/loss) between groups. After controlling for age, race, and primary site, EES was associated with superior EFS (hazard ratio = 0.69; 95% confidence interval: 0.50-0.95; P = 0.02). Among patients with EES, age ≥18, nonwhite race, and elevated baseline erythrocyte sedimentation rate were independently associated with inferior EFS. CONCLUSION: Clinical characteristics, but not key tumor genomic features, differ between EES and skeletal ES. Extraskeletal origin is a favorable prognostic factor, independent of age, race, and primary site.
BACKGROUND: The prognostic significance of having extraskeletal (EES) versus skeletal Ewing sarcoma (ES) in the setting of modern chemotherapy protocols is unknown. The purpose of this study was to compare the clinical characteristics, biologic features, and outcomes for patients with EES and skeletal ES. METHODS:Patients had localized ES and were treated on two consecutive protocols using five-drug chemotherapy (INT-0154 and AEWS0031). Patients were analyzed based on having an extraskeletal (n = 213) or skeletal (n = 826) site of tumor origin. Event-free survival (EFS) was estimated using the Kaplan-Meier method, compared using the log-rank test, and modeled using Cox multivariate regression. RESULTS:Patients with extraskeletal ES (EES) were more likely to have axial tumors (72% vs. 55%; P < 0.001), less likely to have tumors >8 cm (9% vs. 17%; P < 0.01), and less likely to be white (81% vs. 87%; P < 0.001) compared to patients with skeletal ES. There was no difference in key genomic features (type of EWSR1 translocation, TP53 mutation, CDKN2A mutation/loss) between groups. After controlling for age, race, and primary site, EES was associated with superior EFS (hazard ratio = 0.69; 95% confidence interval: 0.50-0.95; P = 0.02). Among patients with EES, age ≥18, nonwhite race, and elevated baseline erythrocyte sedimentation rate were independently associated with inferior EFS. CONCLUSION: Clinical characteristics, but not key tumor genomic features, differ between EES and skeletal ES. Extraskeletal origin is a favorable prognostic factor, independent of age, race, and primary site.
Authors: Antoine Italiano; Yun Shao Sung; Lei Zhang; Samuel Singer; Robert G Maki; Jean-Michel Coindre; Cristina R Antonescu Journal: Genes Chromosomes Cancer Date: 2011-11-10 Impact factor: 5.006
Authors: W Shannon Orr; W Shannon Orr; Jason W Denbo; Catherine A Billups; Jianrong Wu; Fariba Navid; Bhaskar N Rao; Andrew M Davidoff; Matthew J Krasin Journal: Ann Surg Oncol Date: 2012-06-28 Impact factor: 5.344
Authors: S Gururangan; N M Marina; X Luo; D M Parham; C Y Tzen; C A Greenwald; B N Rao; L E Kun; W H Meyer Journal: J Pediatr Hematol Oncol Date: 1998 Jan-Feb Impact factor: 1.289
Authors: G Bacci; S Ferrari; P Rosito; M Avella; E Barbieri; P Picci; A Battistini; A Brach del Prever Journal: Minerva Pediatr Date: 1992 Jul-Aug Impact factor: 1.312
Authors: Hendrik van den Berg; Richard C Heinen; Heleen J van der Pal; Johannes H M Merks Journal: Pediatr Hematol Oncol Date: 2009-06 Impact factor: 1.969
Authors: M Henry-Amar; S Friedman; M Hayat; R Somers; J H Meerwaldt; P Carde; J M Burgers; J Thomas; M Monconduit; E M Noordijk Journal: Ann Intern Med Date: 1991-03-01 Impact factor: 25.391
Authors: S Salah; F Abuhijla; T Ismail; S Yaser; I Sultan; H Halalsheh; A Shehadeh; S Abdelal; A Almousa; O Jaber; R Abu-Hijlih Journal: Clin Transl Oncol Date: 2019-08-19 Impact factor: 3.405
Authors: Augustine M Saiz; Alicia A Gingrich; Robert J Canter; Amanda R Kirane; Arta M Monjazeb; R Lor Randall; Steven W Thorpe Journal: Sarcoma Date: 2019-04-24
Authors: Paweł Kabata; Sonia Kaniuka-Jakubowska; Wanda Kabata; Joanna Lakomy; Wojciech Biernat; Krzysztof Sworczak; Janusz Jaśkiewicz; Maciej Świerblewski Journal: Front Endocrinol (Lausanne) Date: 2017-10-27 Impact factor: 5.555